Navigation Links
The Medicines Company's Cangrelor - Is it better than Plavix for Acute Coronary Syndrome?
Date:11/26/2013

DUBLIN, Nov. 26, 2013 /PRNewswire/ --Research and Markets (http://www.researchandmarkets.com/research/h45rfk/the_medicines) has announced the addition of the "The Medicines Company's Cangrelor - Is it better than Plavix for Acute Coronary Syndrome?" report to their offering.

(Logo: http://photos.prnewswire.com/prnh/20130307/600769)

Cangrelor is a reversible, intravenous inhibitor of the P2Y12 receptor whose effect is to inhibit adenosine diphosphate-induced platelet aggregation. The Medicines Company is developing it for use in the setting of patients undergoing percutaneous coronary intervention procedures (PCI), specifically those who have not used Plavix or other P2Y12 inhibitors in the prior week. Two previous phase III trials failed to meet their primary endpoints. Thus, approval hangs on the results of a third trial, CHAMPION-PHOENIX that should report before year-end. This report explores the probability of a favorable phase III outcome, eventual approval, and the market opportunity.

Key Topics Covered:

INTRODUCTION

1. Acute coronary syndromes (ACS)

2. Thrombosis is at the center of causality

3. Clinicians use several approaches to platelet inhibition


CANGRELOR

1. Phase I/II trials

2. Pivotal trials


CLINICAL AND REGULATORY DISCUSSION

1. Why did CHAMPION-PCI and CHAMPION-PLATFORM fail?

2. Given the PCI and PLATFORM results, what are the lessons for PHOENIX?

3. Are there meaningful safety concerns associated with cangrelor?

4. Are there any bleeding concerns?

5. Possible adverse pulmonary effects of cangrelor

6. What are the regulatory issues that cangrelor will face?

7. Other relevant FDA guidance

8. In summary

MARKET OPPORTUNITY

1. Overview of issues

2. Market estimates

3. Pipeline products

Companies Mentioned

  • Eli Lilly,
  • Bristol Myers Squibb,
  • Astra Zeneca

For more information visit http://www.researchandmarkets.com/research/h45rfk/the_medicines

About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Laura Wood , +353-1-481-1716, press@researchandmarkets.net




'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Worlds Only USDA Certified Organic and FDA Registered Homeopathic Medicines Guaranteed to Work
2. Lilly Expands Strategic Partnership with Chinese Manufacturer Novast to Serve Chinese Patients with High-Quality Branded Generic Medicines
3. Warning: Not All Cold Sore Medicines Are Created Equal
4. Kick Off Summer Vacation With Five Simple Tips to Safely Store Medicines While Traveling
5. Global pharmaceutical industry calls for broad-based cooperation to fight online sales of counterfeit medicines around the world
6. Unigene Provides Update Following Recent EMA Recommendation on Calcitonin-Containing Medicines
7. New Research Reveals Extent of Poor-Quality Antimalarial Medicines in South American Countries
8. Watson Applauds GPhA Study Demonstrating $1 Trillion in Prescription Drug Savings from Generic Medicines
9. Sigma-taus Antimalarial Awarded "Project of the Year" 2011 by Medicines for Malaria Venture
10. National Community Pharmacists Association and Purdue Pharma Urge Americans to Safeguard Rx Medicines This Holiday Season
11. PTC Therapeutics Announces European Medicines Agency Validation of Marketing Authorization Application for Ataluren in Duchenne Muscular Dystrophy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Ind. , April 20, 2017  Zimmer Biomet ... in musculoskeletal healthcare, today announced that it will be ... Care Conference at the InterContinental Hotel in ... Zimmer Biomet will present at 11:20 a.m. Eastern Time. ... be accessed via Zimmer Biomet,s Investor Relations website at ...
(Date:4/20/2017)... Research and Markets has announced the addition of the ... Market and Increasing Usage of Complex Biologics during the Forecast Period" ... ... 20 Billion in 2015 to around USD 26 Billion by 2020. ... by Rapidly Expanding Injectables Market and Increasing Usage of Complex Biologics ...
(Date:4/20/2017)... , April 20, 2017  AbbVie (NYSE: ABBV), ... percent (n=145/146) of chronic hepatitis C virus (HCV) ... or 6 and compensated cirrhosis (Child-Pugh A) achieved ... 12 ) with its investigational, pan-genotypic regimen of ... were seen following 12 weeks of G/P treatment ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... ... announces the continuation of its strategic partnership with and platinum sponsorship of Global ... in the safe and effective management of complex spine deformity cases, particularly in ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... Michael Vick ... and transforming the quarterback position. The former overall number one pick in the 2001 ... football career. He holds the record for the most career rushing yards by a ...
(Date:4/24/2017)... , ... April 24, 2017 , ... As part of ... today to honor the victims of the Holocaust and Nazi persecution, Center for ... Hadamar and Auschwitz on its CMATH Champions trip to Germany and Poland next week. ...
(Date:4/24/2017)... ... ... Pink , a national non-profit organization focusing on the prevention and early detection of breast ... proud to announce Katie Thiede as their new Chief Executive Officer. In January, founder Lindsay ... the Board and launched a national search to find a visionary new leader to grow ...
(Date:4/24/2017)... ... ... Veteran Theresa James awoke to the sound of her newly ex-husband breaking ... James depicts every parent’s worst nightmare, when her three children were violently taken from ... throughout my divorce,” James said. “After the death of my children, I continued to ...
Breaking Medicine News(10 mins):